Citations

Clear

6273 citation(s) found for "To, Andrew".

Vocal Modulation and Engagement Effects in Virtual Health Assistant-Guided Gratitude Journaling Among Young Adults
Maxim, Andrew , Franco, Courtny L. , Venkatakrishnan, Roshan , Lok, Benjamin

Mayo Clinic

Proceedings of the 25th ACM International Conference on Intelligent Virtual Agents | October 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.1145/3717511.3747064 Get It

Novel differentially expressed genes and multiple biological pathways for Alzheimer's disease identified in brain tissue from African American donors
Labadorf, Adam , O’Neill, Nicholas K. , Dugger, Brittany N. , Frosch, Matthew P. , Gearing, Marla, Jin, Lee‐Way, Kofler, Julia , Mayeux, Richard , McKee, Ann C. , Miller, Carol A., Murray, Melissa E. , Nelson, Peter T. , Perrin, Richard J. , Tobunluepop, Katarnut, Troncoso, Juan C. , Murray, Melissa E , Dugger, Brittany N , Logue, Mark W. , Dickson, Dennis W. , Flanagan, Margaret E. , Gearing, Marla , Schneider, Julie A. , Stein, Thor D. , Teich, Andrew F. , Wang, Shih‐Hsiu J. , Wang, Zihan , Wolozin, Benjamin , Mez, Jesse , Farrer, Lindsay A.

Mayo Clinic

Alzheimer's & Dementia | October 8, 2025 | Volume: 21 | Issue: 10 | Pages: No page available

10.1002/alz.70629 | PMID 41059714 Get It

Abstract INTRODUCTION Few African American (AA) donors have been included in post mortem Alzheimer's disease (AD) studies compared to European‐ancestry (EA) individuals. METHODS We generated transcriptome‐wide bulk pre‐frontal cortex (PFC) gene expression data from 125 AA donors with neuropathologically determined AD and 82 AA controls. RESULTS Transcriptome‐wide significant differential expression was observed with 482 genes. The most significant, ADAMTS2 , showed 1.52 times higher expression in AD cases ( p = 2.96x10 −8 ). Comparison of findings with those from a recent gene expression study of EA brain donors revealed substantial concordance, including ADAMTS2 . Other associations not observed in EA results may be especially relevant to AD risk in the AA population. Examination of AA AD GWAS‐implicated variants identified several expression quantitative trait loci. CONCLUSION This first large‐scale AA brain AD gene expression study identified many differentially expressed genes, including ADAMTS2 , and supports gene expression as a molecular pathway underlying the impact of several AA AD risk variants. Highlights We performed the largest African American brain tissue Alzheimer's disease (AD) gene expression study. Expression differences for 482 genes, notably ADAMTS2 , were study‐wide significant. Many significant differentially expressed genes are involved in energy metabolism. Several previously known AD‐associated variants in African Americans are eQTLs. These results advance knowledge of the genetic basis of AD in the AA population.
Innovations in Heart Transplantation: Partial Heart Transplantation and Xenotransplantation
Silvano, Zachary T. , Alexander, Vincent S , Choppara, Sreeja, Javed, Herra , Rajab, Taufiek Konrad, Rajab, Taufiek Konrad , Treffalls, John, Vogel, Andrew D. , Treffalls, John A.

Mayo Clinic

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | October 8, 2025 | Volume: 20 | Issue: 5 | Pages: 435-441

10.1177/15569845251375442 | PMID 41058154 Get It

Despite efforts to improve donor heart allocation policies, geographic disparities, logistical challenges and patient criteria limit organ availability. However, recent surgical innovations offer potential solutions. These include partial heart transplantation and xenotransplantation. Partial heart transplantation is a new procedure with the potential to address several clinical challenges in treating congenital heart defects. Cardiac xenotransplantation involves the transplantation of genetically modified porcine hearts into humans, offering a potential solution to the shortage of donor organs. Although immunologic barriers and ethical concerns remain, ongoing research aims to mitigate the risks and optimize outcomes, providing hope for patients in need. These innovative surgical approaches offer promising avenues for addressing the critical shortage of donor hearts and with ongoing research, may hold the potential to revolutionize heart transplantation, and improve outcomes for patients facing terminal heart failure.
Adaptation and Performance of the Self‐Report‐Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort
Cerhan, James R. , Соколова, Т. Н. , Cahn, Elliot, Tsang, Mazie , Strouse, Christopher , Hildebrandt, Michelle A.T. , Feldman, Andrew L. , Jaye, David L. , Martin, Peter , Cohen, Jonathon B. , Lossos, Izidore S. , Friedberg, Jonathan W. , Thompson, Carrie A. , Flowers, Christopher R. , Sokolova, Tereza, Cahn, Elliott J, Strouse, Christopher S , Rosenthal, Allison , Feldman, Andrew L , Jaye, David L , Martin, Peter , Cohen, Jonathon B , Kahl, Brad S , Lossos, Izidore S , Friedberg, Jonathan W , Nastoupil, Loretta J , Link, Brian K , Habermann, Thomas , Maurer, Matthew , Casulo, Carla , Thompson, Carrie A , Williams, Annalynn M , Flowers, Christopher R , Cerhan, James R , Hildebrandt, Michelle A T , Tsang, Mazie , Sokolova, Tereza, Kahl, Brad S. , Nastoupil, Loretta J. , Link, Brian K. , Habermann, Thomas M. , Maurer, Matthew J. , Casulo, Carla

Mayo Clinic

Hematological Oncology | October 8, 2025 | Volume: 43 | Issue: 6 | Pages: No page available

10.1002/hon.70137 | PMID 41057230 Get It

ABSTRACT Newly diagnosed patients with non‐Hodgkin lymphoma (NHL) often have a history of other diseases, and these comorbidities can impact patient treatment and management options, as well as overall survival (OS). We developed the Lymphoma Epidemiology of Outcomes (LEO) comorbidity index (LCI) as a sum of 10 comorbidities adapted from the Self‐Report‐Generated Charlson Comorbidity Index (SRG‐CCI) for use in the LEO cohort, a national prospective study of newly diagnosed NHL. Of the 5502 participants with self‐reported comorbidity data, 3107 (56.4%) were male and the mean age at diagnosis was 60.9 years (range, 18–99 years). The LCI ranged from 0 to 6, with 48.6% having 0, 30.2% having 1, 21.2% having 2 or more comorbidities. With a median follow‐up of 62.4 months among surviving participants, 2099 patients had an event and 1219 died. Continuous LCI similarly predicted both 1‐year mortality (c‐statistic = 0.654) and OS (c‐statistic = 0.655), while it showed a weaker but still statistically significant predictive ability for lymphoma‐specific (c‐statistics = 0.617) and event‐free (c‐statistic = 0.574) survival. Participants with 1 (HR = 1.21, 95% CI 1.05–1.39) and 2+ (HR = 1.80, 95% CI 1.56–2.08) comorbidities had inferior OS compared to those with no comorbidities after adjustment for age and sex (c‐statistic = 0.654), and performance strengthened after adjustment for the International Prognostic Index (c‐statistic = 0.672). LCI predicted OS most strongly in marginal zone (c‐statistics = 0.748) and weakest in T‐cell (c‐statistic = 0.579) lymphoma. The cumulative incidence of death due to lymphoma, lymphoma treatment, and other causes all increased with increasing comorbidities, with the greatest increase observed for death due to other causes. The LCI performs comparable to other published comorbidity indices, supporting its use in the LEO cohort to better model real‐world outcomes and more generally providing an approach to implementing comorbidity indices in cancer survivorship cohorts.
Factors Associated With More Medication Trials Before Surgical Evaluation and Postsurgical Outcomes in Pediatric Drug-Resistant Epilepsy
Samanta, Debopam , Newell, Grace, Caraway, Avery Robert, Brock, Emily, Albert, Gregory W. , Novotny, Edward J. , Cabacar, Dewi Frances Depositario, Gaillard, William D. , Tatachar, Priyamvada , Bolton, Jeffrey , Romanowski, Erin Fedak , Alexander, Allyson , Auguste, Kurtis I. , Bernardo, Danilo , Ostendorf, Adam P. , Karia, Samir , Karakas, Cemal , Pichon, P, Olaya, Joffre , Shrey, Daniel W. , Reddy, Shilpa B. , Ganesh, Abhinaya, Hauptman, Jason S. , Singh, Rani K. , Ciliberto, Michael A. , Marashly, Ahmad , Nangia, Srishti, Arredondo, Kristen H. , Miller, D. , Sattar, Shifteh , Montenegro, Maria Augusta , Agarwal, Nitin , Galán, Fernando , Wagner, Janelle L. , Knox, Andrew , Perry, Μ. Scott , Caraway, Avery R. , Caraway, Avery Robert , Novotny, Edward J , Depositario Cabacar, Dewi Frances , Oluigbo, Chima O , Gaillard, William D , Tatachar, Priyamvada , Bolton, Jeffrey Brian , Wong-Kisiel, Lily C. , Fedak Romanowski, Erin , McNamara, Nancy A , Eschbach, Krista , Alexander, Allyson L , Auguste, Kurtis I , Gonzalez-Giraldo, Ernesto , Bernardo, Danilo , Ostendorf, Adam P , Coryell, Jason , Karia, Samir , Karakas, Cemal , Javarayee, Pradeep K , Pichon, Pilar D , Shrey, Daniel W , Reddy, Shilpa B , Ganesh, Abhinaya , Hauptman, Jason , Singh, Rani K , Ciliberto, Michael A , Marashly, Ahmad , Grinspan, Zachary , Arredondo, Kristen H , Miller, Derryl J , Montenegro, Maria , Agarwal, Nitin , Galan, Fernando N , Abel, Taylor J , Knox, Andrew T , Perry, Michael Scott , Newell, Grace, Brock, Emily, Oluigbo, Chima , Wong‐Kisiel, Lily C. , McNamara, Nancy , Eschbach, Krista , Gonzalez‐Giraldo, Ernesto , Coryell, Jason , Javarayee, Pradeep , Grinspan, Zachary M. , Abel, Taylor J.

Mayo Clinic

Neurology | October 7, 2025 | Volume: 105 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000214198 | PMID 41056528 Get It

Association between housing instability and frailty among people with HIV
Fahey, Carolyn A. , Drumright, Lydia N. , Fredericksen, Rob J. , Yendewa, George A. , Karris, Maile , Mixson, L. Sarah , Agil, Deana , Burkholder, Greer , Bamford, Laura , Fleming, Julia, Hahn, Andrew W. , Austad, Steven N. , Cachay, Edward R. , Kitahata, Mari M. , Saag, Michael S, Crane, Heidi M. , Whitney, Bridget M. , Cachay, Edward, Drumright, Lydia N , Ruderman, Stephanie A. , Napravnik, Sonia , Webel, Allison R. , Mayer, Kenneth Hugh , Fleming, Julia, Kritchevsky, Stephen B. , Delaney, Joseph A. , Saag, Michael S.

Mayo Clinic

AIDS | October 7, 2025 | Volume: 40 | Issue: 1 | Pages: 90-99

10.1097/qad.0000000000004370 | PMID 41056002 Get It

Background: Housing instability and HIV are both associated with early onset of aging-related health conditions, including frailty. However, little is known about the relationship between housing and frailty among people with HIV. Methods: We analyzed data on adults in HIV care collected during routine clinical visits at 6 sites within the US Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) between 2019 and 2024. We measured frailty using a previously validated approach, defined as having at least three of four components (fatigue, weight loss, immobility, inactivity) vs. less than three components. Housing status was based on self-perceived living situation in the past month (“Stable,” “Unstable,” “Homeless,” or “Don’t know”). We estimated the association between most recent housing status and frailty with prevalence ratios from relative risk regression adjusted for sociobehavioral and clinical characteristics. Results: Among 6961 people with HIV (84% men, 16% women) with a median age of 52 years (IQR: 40–60), 11% ( n = 760) were frail and 9% ( n = 625) were unstably housed (5% unstable, 3% homeless, 1% do not know). Compared to individuals with stable housing, the prevalence of frailty more than doubled among those experiencing unstable housing [prevalence ratio = 2.41, 95% confidence interval (95% CI): 1.95–2.97] or homelessness (prevalence ratio = 2.05, 95% CI: 1.56–2.69). Stratified analyses indicated stronger associations among younger vs. older individuals and among those virally suppressed vs. unsuppressed. Conclusion: Housing instability and frailty were both prevalent and strongly associated among adults in HIV care, including within younger and virally suppressed subgroups. These findings highlight the importance of social determinants of health for clinical outcomes among all people with HIV.
Impact of oncology second opinion consultation on anxiety levels and confidence in the organization.
Sullivan, Molly , Hellard, Sally, Jahanzeb, Mohammad , Leming, Philip D. , Randall, Marcus E. , Guinigundo, Andrew S, Hunt, Jillian M., Reid, Amanda, Smeltzer, Matthew, Zoň, Robin , Barrett, William , Jazieh, Abdul Rahman , Reid, Amanda, Jazieh, Khalid

Mayo Clinic

JCO Oncology Practice | October 7, 2025 | Volume: 21 | Issue: 10_suppl | Pages: 406-406

10.1200/op.2025.21.10_suppl.406 Get It

406 Background: Anxiety is highly prevalent among oncology patients, often arising from uncertainty around diagnosis, treatment options, and prognosis. Elevated anxiety can impair decision-making, reduce treatment adherence, and diminish overall quality of life. Effective second opinion consultations may help mitigate anxiety and increase patients’ confidence in recommending healthcare services to others. Our study evaluates the impact of oncology second opinion (OSO) consultations on anxiety level (AL) and confidence in the organization (CIO) providing the second opinion, i.e., Cincinnati Cancer Advisors (CCA) and Naples Cancer Advisors (NCA). Methods: The study included patients with cancer diagnoses, age ≥18 years, who were served in person for OSO at CCA and NCA. A survey was used before and after consultation, measuring AL (scale 1- 10) and CIO level (scale 1 - 10), assessed by asking patients how likely they would refer loved ones to the organization. After the content and face validation, patients completed the survey anonymously, put it in a sealed envelope, and dropped it in a dedicated box. Data was analyzed using paired t-tests to compare the change from pre- to post-consultation scores. Spearman’s correlation test was used to assess the relation between the changes in AL and CIO. Statistical significance was assessed using an alpha-level of 0.05. Analyses were conducted via R and R Studio (version 2025.5.1.513). Results: Overall, 46 consecutive patients participated (45 completed AL pre and post visit survey and 43 completed the CIO pre and post visit survey). The mean pre-consultation anxiety score was 5.92 (SD = 2.58), and the post-consultation score was 3.87 (SD = 2.10), demonstrating a significant reduction (mean paired difference = -2.05; p < 0.0001). The mean pre-consult CIO was 8.21 (SD = 2.03), increasing to 9.73 post-consultation (SD = 0.53), indicating a significant improvement (mean paired difference = 1.66; p < 0.0001). The correlation between changes in AL and CIO was not statistically significant, which may be attributed to the high baseline CIO scores (ceiling effect) and the small sample size. Conclusions: Oncology second opinion was associated with a marked decrease in patient AL and a significant increase in CIO. The patient survey will continue to recruit additional participants to increase the sample size and explore the correlation between changes in AL and CIO. Studying the downstream impact on patient experience and outcome is warranted.
Outcomes of Early-Life Focal Cortical Dysplasia–Related Epilepsy
Cohen, Nathan T. , Depositario‐Cabacar, Dewi, Ostendorf, Adam P. , Wong‐Kisiel, Lily C. , Romanowski, Erin Fedak , McNamara, Nancy , Tatachar, Priyamvada , Eschbach, Krista , Alexander, Allyson , Pichon, P, Ciliberto, Michael A. , Bernardo, Danilo , Auguste, Kurtis I. , Arredondo, Kristen H. , Reddy, Shilpa B. , Ganesh, Abhinaya, Marashly, Ahmad , Singh, Rani K. , Bolton, Jeffrey , Karia, Samir , Karakas, Cemal , Lin, Jenny , Knox, Andrew , Samanta, Debopam , Armstrong, Dallas , Pavuluri, Spriha , Hyslop, Ann , Galán, Fernando , Miller, D. , Hauptman, Jason S. , Caraway, Avery Robert, Perry, Μ. Scott , Caraway, Avery R. , Oluigbo, Chima O , Ostendorf, Adam P , Wong-Kisiel, Lily C. , Fedak Romanowski, Erin , McNamara, Nancy A , Tatachar, Priyamvada , Eschbach, Krista , Alexander, Allyson L , Pichon, Pilar D , Ciliberto, Michael A , Gonzalez-Giraldo, Ernesto , Bernardo, Danilo , Auguste, Kurtis I , Coryell, Jason , Arredondo, Kristen H , Novotny, Edward J , Reddy, Shilpa B , Ganesh, Abhinaya , Marashly, Ahmad , Javarayee, Pradeep K , Singh, Rani K , Bolton, Jeffrey Brian , Grinspan, Zachary , Karia, Samir , Karakas, Cemal , Lin, Jenny , Knox, Andrew T , Wolf, Steven , Abel, Taylor J , Samanta, Debopam , Armstrong, Dallas Michael , Hyslop, Ann , Galan, Fernando N , Miller, Derryl J , Hauptman, Jason , Caraway, Avery Robert , Perry, Michael Scott , Gaillard, William D , Oluigbo, Chima , Gonzalez‐Giraldo, Ernesto , Coryell, Jason , Novotny, Edward J. , Javarayee, Pradeep , Grinspan, Zachary M. , Wolf, Steven M. , Abel, Taylor J. , Gaillard, William D.

Mayo Clinic

Neurology Clinical Practice | October 6, 2025 | Volume: 15 | Issue: 6 | Pages: No page available

10.1212/cpj.0000000000200539 | PMID 41070137 Get It

Outcomes in Patients With Immune Checkpoint Inhibitor–Related Myopathy and Prolonged Follow-Up
Segal‬‏, Yahel , Mangioris, Georgios , Toledano, Michel , Kottschade, Lisa A. , McKeon, Andrew , Naddaf, Elie , Pittock, Sean J. , Dubey, Divyanshu , Ζεκερίδου, Αναστασία , Pittock, S J , Kottschade, Lisa, Flanagan, E P , McKeon, Andrew , Stoff, Ronen, Naddaf, Elie , Dubey, Divyanshu , Zekeridou, Anastasia , Flanagan, Eoin P. , Stoff, Ronen , Segal, Yahel

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | October 6, 2025 | Volume: 12 | Issue: 6 | Pages: No page available

10.1212/nxi.0000000000200484 | PMID 41052400 Get It

Modulation of host lung immunity in Pneumocystis pneumonia: a review of current concepts and future prospects for novel adjunctive immune-based therapies
Kottom, Theodore J. , Kottom, Theodore J , Limper, Andrew H.

Mayo Clinic

The Journal of Immunology | October 6, 2025 | Volume: 215 | Issue: 3 | Pages: No page available

10.1093/jimmun/vkaf269 | PMID 41051917 Get It

Abstract Pneumocystis jirovecii pneumonia remains a significant cause of mortality and morbidity in immunocompromised populations worldwide. Mortality rates range from 5% to 30% in HIV-positive individuals and 4% to 76% in those without HIV. Recognizing its public health impact, the World Health Organization (WHO) included Pneumocystis jirovecii in its 2022 “Fungal Priority Pathogens” list. In this review, we will summarize published findings over the last 14 years on the immunopathogenic mechanisms underlying Pneumocystis pneumonia–related lung injury and examine the potential for targeting these pathways in adjunctive immune modulation therapy. Notably, recent studies have identified promising immune-based interventions, including PD-1/PD-L1 blockade and IL-7 therapy, which may enhance pathogen clearance while controlling damaging inflammation. Additionally, small molecule inhibitors such as BRD5529 and ALW-II-41-27 have shown potential in reducing lung injury by modulating proinflammatory signaling pathways in Pneumocystis pneumonia.